Visium SA has successfully closed its first institutional funding round, aimed at expanding its AI-driven solutions for regulated industries across Europe and the U.S.
The funding round, co-led by Columbus Venture Partners and Concentric, involved participation from a select group of unicorn founders. Although the exact amount raised remains undisclosed, the investment is set to enhance Visium's team and product capabilities significantly. The company has already earned recognition as one of the Financial Times’ Top 100 Fastest Growing Companies in Europe.
CEO Alen Arslanagic emphasized that this funding is more than just financial support; it aligns Visium with investors who share a vision for transforming operational processes in life sciences. The dual approach of combining consulting with product development allows Visium to address real operational challenges while providing scalable solutions. This strategy is particularly relevant as generative AI is increasingly seen as a key driver of efficiency in drug development and other complex workflows.
The involvement of Columbus Venture Partners, known for its expertise in biotechnology, and Concentric's hands-on investment strategy highlights the growing recognition of AI's transformative potential in the life sciences sector. As Visium prepares for its next growth phase, the company is also strengthening its leadership team with new appointments to its Board of Directors and Advisory Board, further enhancing its expertise in the field.